Analyst Price Targets — LFST
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 14, 2026 9:44 am | — | Barclays | $13.00 | $10.88 | TheFly | LifeStance price target raised to $13 from $9 at Barclays |
| July 13, 2026 9:45 am | Steve Dechert | KeyBanc | $13.00 | $10.71 | TheFly | LifeStance price target raised to $13 from $11 at KeyBanc |
| June 5, 2026 10:07 am | Scott Fidel | Goldman Sachs | $9.00 | $7.64 | StreetInsider | Goldman Sachs Starts Lifestance Health Group (LFST) at Neutral |
| May 8, 2026 11:20 am | — | Canaccord Genuity | $11.00 | $8.85 | TheFly | LifeStance price target raised to $11 from $10 at Canaccord |
| February 25, 2026 6:56 pm | — | BMO Capital | $10.00 | $7.41 | TheFly | LifeStance price target raised to $10 from $8 at BMO Capital |
| February 2, 2026 12:09 pm | David Larsen | BTIG | $11.00 | $7.07 | TheFly | LifeStance price target raised to $11 from $10 at BTIG |
| January 8, 2026 12:43 pm | Steve Dechert | KeyBanc | $8.50 | $7.30 | TheFly | LifeStance price target raised to $8.50 from $6.50 at KeyBanc |
| January 8, 2026 12:03 pm | Richard Close | Canaccord Genuity | $9.00 | $7.30 | TheFly | LifeStance price target raised to $9 from $8 at Canaccord |
| December 12, 2025 12:29 pm | — | BTIG | $10.00 | $6.77 | TheFly | LifeStance price target raised to $10 from $9 at BTIG |
| December 8, 2025 9:15 pm | Peter Warendorf | Barclays | $8.00 | $6.41 | TheFly | LifeStance initiated with an Overweight at Barclays |
Latest News for LFST
SCOTTSDALE, Ariz., July 16, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental healthcare, will issue its second quarter 2026 earnings release before the market opens on Thursday, August 6, 2026.
Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
LifeStance Health (LFST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.
The average of price targets set by Wall Street analysts indicates a potential upside of 37.3% in LifeStance Health (LFST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LFST.
U.S. House Trading
No House trades found for LFST.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.